Optimistic Outlook: Buy Rating on Biohaven Ltd. for Strategic Approach and Promising R&D Pipeline
Buy Rating Backed by Biohaven Ltd.'s Promising Clinical Pipeline and Pharmacokinetic Advancements
Biohaven Ltd. (BHVN) Gets a Buy From RBC Capital
Buy Rating for Biohaven Ltd. Backed by Strong Clinical Data and Strategic Financial Position
Buy Rating on Biohaven Ltd. Affirmed Amid Promising BHV-1300 Clinical Trial Results and Undervalued Stock Potential
Analysts Have Conflicting Sentiments on These Healthcare Companies: Biohaven Ltd. (BHVN), HCA Healthcare (HCA) and Kiniksa Pharmaceuticals (KNSA)
Buy Rating Affirmed for Biohaven Ltd. Amidst Expansion and Progress in R&D Programs
Analysts Conflicted on These Healthcare Names: NeueHealth Inc (NEUE), BridgeBio Pharma (BBIO) and Biohaven Ltd. (BHVN)
Biohaven Ltd. (BHVN) Gets a Buy From RBC Capital
Optimistic Outlook: Buy Rating Affirmed for Biohaven Ltd. Amid Promising Pipeline and Synergistic Drug Potential
Analysts' Top Healthcare Picks: Biohaven Ltd. (BHVN), Sarepta Therapeutics (SRPT)
Biohaven Ltd. (BHVN) Gets a Buy From TD Cowen
Analysts Offer Insights on Healthcare Companies: Xenon (XENE), Biohaven Ltd. (BHVN) and Arrowhead Pharmaceuticals (ARWR)
Buy Rating Affirmed on Biohaven Ltd. Amidst Pipeline Potential and Upcoming Developments
RBC Capital Sticks to Their Buy Rating for Biohaven Ltd. (BHVN)
Analysts Are Bullish on Top Healthcare Stocks: Biohaven Ltd. (BHVN), Becton Dickinson (BDX)
Buy Rating Affirmed for Biohaven Ltd. Amid Positive Clinical Outlook and Pipeline Potential
Analysts Offer Insights on Healthcare Companies: Biohaven Ltd. (BHVN), Zoetis (ZTS) and Ginkgo Bioworks Holdings (DNA)
Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), AstraZeneca (AZN) and Biohaven Ltd. (BHVN)
Buy Rating Affirmed: Biohaven Ltd. Poised for Key Milestones With Diverse Portfolio and Promising Lead Molecule BHV-7000
No Data
No Data